All In Biotech

NDA 219935 · Sagent

Famotidine

Famotidine · Intravenous · Histamine-2 Receptor Antagonist

Discontinued

Last checked: Nov 19, 2026Latest source record: Jul 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Jul 16, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

147

23 Phase 3, 15 recruiting

FAERS reports

78,942

53,278 serious, 7,746 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 6, 2026.

Famotidine Injection is indicated for use in hospitalized adults, or as an alternative to oral famotidine in adults, for the treatment of: active duodenal ulcer (DU). active gastric ulcer (GU). symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by endoscopy. treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of duodenal ulcer recurrence. FAMOTIDINE Injection is a histamine-2 (H 2 ) receptor antagonist indicated: In hospitalized adults, or as an alternative to oral famotidine in adults, for the treatment of: active duodenal ulcer (DU). active gastric ulcer (GU). symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by endoscopy. treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of DU recurrence. In hospitalized pediatric patients 1 year of age and older, or as an alternative to oral famotidine in pediatric patients 1 year of age and older, for the treatment of: peptic ulcer disease. Pediatric Patients 1 Year of Age and Older Famotidine Injection is indicated in hospitalized pediatric patients 1 year of age and older, or as an alternative to oral famotidine in pediatric patients 1 year of age and older, for the treatment of peptic ulcer disease.

Mechanism: Famotidine is a competitive inhibitor of histamine H 2 -receptors. The primary clinically important pharmacologic activity of famotidine is inhibition of gastric secretion. Both the acid concentration and volume of gastric secretion are suppressed by famotidine, while changes in pepsin secretion are proportional to volume output.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 16, 2025 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabel
3 products under this application
  • FAMOTIDINE · FAMOTIDINE 20MG/5ML (4MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • FAMOTIDINE · FAMOTIDINE 40MG/10ML (4MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • FAMOTIDINE · FAMOTIDINE 200MG/50ML (4MG/ML) · SOLUTION, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Famotidine" as an intervention, any sponsor and status, largest first.

All 147 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea5,149
  • fatigue4,939
  • diarrhoea4,819
  • off label use4,129
  • dyspnoea3,819
  • drug ineffective3,758
  • chronic kidney disease3,530
  • headache3,502
  • vomiting3,144
  • pain3,086
  • dizziness2,919
  • acute kidney injury2,806

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004678
2005672
2006635
2007628
2008800
2009663
2010963
20111,476
20121,834
20131,084
20141,359
20152,195
20162,700
20173,026
20184,037
20194,683
20206,218
20216,355
20226,923
20237,023
20248,242
20259,224
20267,520

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Famotidine (Famotidine In NaCl,Iso-Osm/PF)

2024 spending

$663

Beneficiaries

56

90 claims

Per beneficiary

$12

$0.16 per unit

View as table
YearSpending
2020$1,295
2021$912
2022$426
2023$846
2024$663

Part D: Famotidine (Famotidine/PF)

2024 spending

$74K

Beneficiaries

1,718

9,948 claims

Per beneficiary

$43

$0.48 per unit

View as table
YearSpending
2020$63,762
2021$76,737
2022$74,809
2023$69,118
2024$73,581

Part D: Famotidine* (Famotidine)

2024 spending

$179M

Beneficiaries

3,926,510

14,044,674 claims

Per beneficiary

$46

$0.16 per unit

View as table
YearSpending
2020$143,448,123
2021$200,948,982
2022$181,466,099
2023$202,809,307
2024$178,983,102

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 566 on PubMed

Sponsor: Sagent

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.